Semaglutide effects on visceral fat and liver in people with chronic kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational imaging study comparing adults with type 2 diabetes and chronic kidney disease who are taking semaglutide to those who are not. Participants will undergo MRI scans to measure fat around the heart, liver, and kidneys, including liver fat quantification, and study staff will collect medical history, medications, and basic demographic and clinical data. The study enrolls adults with T2DM for at least 18 months and CKD stages G1–G4, and does not alter participants' treatments. Data will be analyzed to see associations between semaglutide use and visceral or hepatic fat measures in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ≥ 18 years of age.
* Patients diagnosed with T2DM (\>18 months) and CKD in stages G1, G2, G3a, G3b and G4; the CKD staging will be established according to the eGFR as per the KDIGO guidelines (G1: eGFR ≥90 ml/min/1.73m2; G2: 60-89 ml/min/1.73m2; G3a: 45-59 ml/min/1.73m2; G3b: 30-44 ml/ min/1.73m2; G4: 15-29 ml/ min/1.73m2).
* Patients with T2DM and CKD, with or without semaglutide treatment.
* Patients who voluntarily agree to participate and sign informed consent.

Exclusion Criteria:

* Patients \<18 years of age.
* Pregnant, breastfeeding, or an intention of becoming pregnant or not using adequate contraceptive measures (including country-specific adequate measures, if any)
* Patients diagnosed with T2DM and CKD in stage G5 or stage G4 requiring dialysis as per KDIGO guidelines.
* Previous participation in this trial (screened or randomized)
* Patients diagnosed with neuropsychiatric diseases that prevent them from understanding the benefits/risks associated with the project or voluntarily choosing to participate.
* Known or suspected allergy to trial medication(s), excipients, or related products
* Contraindications to study medication(s), worded specifically as stated in the Product Monograph
* Refusal to participate or consent revocation.

Where it's running

• Mazankowski Alberta Heart Institute
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Principal investigator: Paolo Raggi, M.D — University of Alberta

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How incretin treatments affect muscle mass and function in people with overweight or obesity

  This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.

  Recruiting Radboud University Medical Center · Amsterdam and 1 other locations · NCT07929831

• Dose find for remimazolam plus alfentanil for gastroscopy in obese adults

  This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07925684

• Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults

  This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.

  Recruiting Yuzuncu Yil University · Van · NCT07901777

• Gut barrier and inflammation after fast-food overfeeding in adults

  This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.

  Recruiting University Hospital, Gentofte, Copenhagen · Hellerup · NCT07893743

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• GLP-1 weight‑loss medicine: finding who will benefit most

  This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.

  Recruiting Phase 4 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07870538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.